E. Stankevich

发表

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Israel Lowy, Mark Selby, Drew M Pardoll, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis

A. Hauschild, D. Schadendorf, I. Lowy, 2021, Journal for ImmunoTherapy of Cancer.

Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC)

T. Dorff, C. Higano, I. Lowy, 2008 .

PD‐1 Blockade with Cemiplimab in Advanced Cutaneous Squamous‐Cell Carcinoma

A. Hauschild, D. Schadendorf, C. Chung, 2018, The New England journal of medicine.

Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.

C. Berking, A. Hauschild, D. Schadendorf, 2020, The Lancet. Oncology.

Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and GM-CSF in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

T. Owonikoko, I. Lowy, K. Papadopoulos, 2021, The oncologist.

Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC)

I. Lowy, H. Berg, R. Scheper, 2008 .

Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort.

I. Lowy, K. Papadopoulos, L. Rosen, 2021, Lung cancer.

Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing

A. Hauschild, D. Schadendorf, I. Lowy, 2020, Journal for immunotherapy of cancer.

First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies

Melissa L. Johnson, G. Weiss, I. Lowy, 2019, Clinical Cancer Research.

Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810

I. Lowy, B. Piening, C. Bifulco, 2016, Journal of Immunotherapy for Cancer.

Primary analysis of phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC).

C. Berking, A. Hauschild, D. Schadendorf, 2019, Journal of Clinical Oncology.

Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up.

A. Hauschild, I. Lowy, R. Gutzmer, 2019, Journal of Clinical Oncology.

Cemiplimab (REGN2810): A fully human anti-PD-1 monoclonal antibody for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)—Initial safety and efficacy from expansion cohorts (ECs) of phase I study.

Melissa L. Johnson, T. Owonikoko, I. Lowy, 2017 .

A phase III, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC).

I. Lowy, D. Rischin, S. Porceddu, 2020 .

Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up.

A. Hauschild, D. Schadendorf, I. Lowy, 2020 .

Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis

John D. Davis, I. Lowy, K. Papadopoulos, 2021, Advances in Therapy.

Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up

A. Hauschild, D. Schadendorf, I. Lowy, 2020 .

PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer.

I. Lowy, K. Papadopoulos, I. Braña, 2020, Gynecologic oncology.

Biochemical and immunologic correlates of clinical response in a combination trial of the GM-CSF-gene transduced allogeneic prostate cancer immunotherapy and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC)

G. Giaccone, I. Lowy, R. Scheper, 2007 .

A first-in-human study of REGN2810, a monoclonal, fully human antibody to programmed death-1 (PD-1), in combination with immunomodulators including hypofractionated radiotherapy (hfRT).

Melissa L. Johnson, G. Weiss, I. Lowy, 2016 .

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

J. Taube, C. Drake, Lieping Chen, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II experience with MDX-1106 (Ono-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies.

C. Drake, I. Lowy, A. Korman, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

J. Taube, C. Drake, Lieping Chen, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.